SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: To evaluate the generality of the NMA chemistry, we applied it to modulation of SCN1A exon 20N splicing, a therapeutic strategy for Dravet syndrome.